SCHEMBL933043

SCHEMBL933043

COC(CCOC(C)=O)OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.46
ALDH1A1 P00352 5/20 0.44
CHRNB2 P17787 3/20 0.43
CHRNA4 P43681 3/20 0.43
CHRM5 P08912 2/20 0.43
CHRM1 P11229 2/20 0.43
CHRM3 P20309 2/20 0.43
CHRNB4 P30926 2/20 0.43
CHRNA3 P32297 2/20 0.43
PGR P06401 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
HTR1A P08908 1/20 0.43
TBXA2R P21731 1/20 0.43
CHRNA7 P36544 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CHRNA10 Q9GZZ6 1/20 0.43
CHRNA9 Q9UGM1 1/20 0.43
TSHR P16473 1/20 0.43
GALR3 O60755 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5198887 0.89 ALOX15 (0.42) ALOX15ALDH1A1CHRNB2CHRNA4CHRM5
SCHEMBL1870953 0.86 ALDH1A1 (0.52) ALOX15ALDH1A1CHRNB2CHRNA4CHRM5
SCHEMBL812118 0.81 ALOX15 (0.46) ALOX15ALDH1A1CHRNB2CHRNA4CHRM5
SCHEMBL1988725 0.79 ADRA2A (0.46) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL28610088 0.79 CHRNB2 (0.53) ALOX15CHRNB2CHRNA4CHRM5CHRM1
SCHEMBL31685161 0.79 ALOX15 (0.48) ALOX15ALDH1A1CHRNB2CHRNA4CHRM5
SCHEMBL14996218 0.79 CHRNB2 (0.35) ALOX15ALDH1A1CHRNB2CHRNA4CHRNB4
SCHEMBL36334 0.79 ALOX15 (0.48) ALOX15ALDH1A1CHRNB2CHRNA4CHRM5
SCHEMBL555904 0.79 THRB (0.50) ALOX15ALDH1A1TSHRTDP1
SCHEMBL16907178 0.79 ALOX15 (0.41) ALOX15ALDH1A1CHRNB2CHRNA4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10307434-B2 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. (SG) 2019-06-04 US disclosed
CN-108191813-A A kind of preparation method of ketal 帕潘纳(北京)科技有限公司 2018-06-22 CN disclosed
CN-108191813-A A kind of preparation method of ketal 帕潘纳(北京)科技有限公司 2018-06-22 CN disclosed
US-9744183-B2 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. (SG) 2017-08-29 US disclosed
US-9744183-B2 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. (SG) 2017-08-29 US disclosed
US-20160347784-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES PTE. LTD. (SG) 2016-12-01 US disclosed
US-20160347784-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES PTE. LTD. (SG) 2016-12-01 US disclosed
US-20120316224-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF ONTORII, INC (US) 2012-12-13 US disclosed
EP-2451461-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF Ontorii, Inc (US) 2012-05-16 EP disclosed
WO-2011005761-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF ONTORII, INC (US) 2011-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316224-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF PNP, RNGTT, TYMP ALOX15 2996/4885ALDH1A1 1085/4885CHRNB2 4549/4885
US-20160347784-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF PNP, RNGTT, TYMP ALOX15 2996/4885ALDH1A1 1085/4885CHRNB2 4549/4885
US-10307434-B2 Nucleic acid prodrugs and methods of use thereof PNP, RNGTT, NSUN2 ALOX15 2776/4885ALDH1A1 899/4885CHRNB2 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.